
|Videos|January 5, 2015
PFS as an Endpoint in Ovarian Cancer Clinical Trials
Author(s)Jason D. Wright, MD
Jason D. Wright, MD, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.
Advertisement
Clinical Pearls
Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.
- PFS is the most commonly used endpoint for ovarian cancer clinical trials.
- PFS is relatively easily measured and can be measured in a timely fashion.
- However, PFS does not always correlate with overall survival.
Olaparib was recently approved for ovarian cancer.Read more > >
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































